Blood Monocyte Chemotactic Protein-1 (MCP-1) and Adapted Disease Activity Score28-MCP-1: Favorable Indicators for Rheumatoid Arthritis Activity

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Feb 6

PMID 23383162

Citations 19

Authors

Lieh-Bang Liou

Wen-Pin Tsai

Chee J Chang

Wan-Ju Chao

Meng-Hsin Chen

Affiliations

Soon will be listed here.

Abstract

Objective: We assessed blood pentraxin 3 (PTX3) and macrophage chemotactic factor-1 (MCP-1) levels as indicators of disease activity in rheumatoid arthritis (RA) patients, because data on disease activity score 28 (DAS28)-erythrocyte sedimentation rate (ESR) and DAS28-C-reactive protein (CRP) are still imperfect.

Methods: In 111 patients with RA, we examined longitudinal and cross-sectional correlations of blood PTX3, MCP-1, CRP, and ESR levels with measures of clinical arthritic activity, namely, swollen joint count (SJC), tender joint count (TJC), visual analog scale for general health (GH), DAS28, and adapted DAS28-MCP-1.

Results: Blood MCP-1, but not PTX3, was significantly correlated with SJC, TJC, DAS28, and DAS28-CRP. DAS28-MCP-1 was strongly correlated with DAS28 (r = 0.984, P<0.001) and DAS28-CRP (r = 0.971, P<0.001), and modestly correlated with CRP (r = 0.350, P<0.001), and ESR (r = 0.386, P<0.001). Similarly, the duration of arthritic symptoms, but not sex, was significantly correlated with variables of arthritic activity. In particular, DAS28-MCP-1 significantly correlated with DAS28 during a 6-month period (r = 0.944, P<0.001; r = 0.951, P<0.001; r = 0.862, P<0.001; and r = 0.865, P<0.001 for month 0, 1, 3, and 6, respectively).

Conclusion: Blood MCP-1 and adapted DAS28-MCP-1, but not blood PTX3, may be useful in monitoring RA activity.

Citing Articles

Effective Assessment of Rheumatoid Arthritis Disease Activity and Outcomes Using Monocyte Chemotactic Protein-1 (MCP-1) and Disease Activity Score 28-MCP-1.

Tsai P, Liou L Int J Mol Sci. 2024; 25(21).

PMID: 39518927 PMC: 11546828. DOI: 10.3390/ijms252111374.

Immunoregulatory Cells and Cytokines Discriminate Disease Activity Score 28-Remission Statuses and Ultrasound Grades in Rheumatoid Arthritis Patients with Non-High Disease Activity.

Liou L, Fang Y, Tsai P, Chen Y, Chang C, Chen C Int J Mol Sci. 2024; 25(16).

PMID: 39201379 PMC: 11354682. DOI: 10.3390/ijms25168694.

Predictors of Remission or Combined Remission and Low Disease Activity in Rheumatoid Arthritis Patients in Taiwan: A Prospective Cohort Study.

Tsai P, Fang Y, Chen Y, Chen C, Chiang W, Chang C J Clin Med. 2024; 13(9).

PMID: 38731049 PMC: 11084563. DOI: 10.3390/jcm13092521.

Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review.

Perera J, Delrosso C, Nerviani A, Pitzalis C Cells. 2024; 13(9.

PMID: 38727279 PMC: 11083059. DOI: 10.3390/cells13090743.

Liou L, Tsai P, Fang Y, Chen Y, Chen C, Lai J Int J Mol Sci. 2023; 24(16).

PMID: 37629178 PMC: 10455111. DOI: 10.3390/ijms241612998.

References

Dessein P, Joffe B, Stanwix A . High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis. J Rheumatol. 2004; 31(6):1095-7. View

Bassi N, Ghirardello A, Blank M, Zampieri S, Sarzi-Puttini P, Mantovani A . IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis. 2010; 69(9):1704-10. DOI: 10.1136/ard.2009.117804. View

Baruah P, Propato A, Dumitriu I, Rovere-Querini P, Russo V, Fontana R . The pattern recognition receptor PTX3 is recruited at the synapse between dying and dendritic cells, and edits the cross-presentation of self, viral, and tumor antigens. Blood. 2005; 107(1):151-8. DOI: 10.1182/blood-2005-03-1112. View

Mauri T, Coppadoro A, Bellani G, Bombino M, Patroniti N, Peri G . Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit Care Med. 2008; 36(8):2302-8. DOI: 10.1097/CCM.0b013e3181809aaf. View

Kuo C, Tsai W, Liou L . Rare copresent rheumatoid arthritis and gout: comparison with pure rheumatoid arthritis and a literature review. Clin Rheumatol. 2007; 27(2):231-5. DOI: 10.1007/s10067-007-0771-2. View

Ellingsen T, Buus A, Stengaard-Pedersen K . Plasma monocyte chemoattractant protein 1 is a marker for joint inflammation in rheumatoid arthritis. J Rheumatol. 2001; 28(1):41-6. View

Taylor W, Harrison A, Highton J, Chapman P, Stamp L, Dockerty J . Disease Activity Score 28-ESR bears a similar relationship to treatment decisions across different rheumatologists, but misclassification is too frequent to replace physician judgement. Rheumatology (Oxford). 2008; 47(4):514-8. DOI: 10.1093/rheumatology/ken004. View

Crowson C, Rahman M, Matteson E . Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. J Rheumatol. 2009; 36(8):1606-10. DOI: 10.3899/jrheum.081188. View

Breviario F, dAniello E, Golay J, Peri G, Bottazzi B, Bairoch A . Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem. 1992; 267(31):22190-7. View

10.

Zhang Z, Cherryholmes G, Mao A, Marek C, Longmate J, Kalos M . High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia. Exp Biol Med (Maywood). 2008; 233(9):1171-80. DOI: 10.3181/0712-RM-328. View

11.

Szyper Kravitz M, Pitashny M, Shoenfeld Y . Protective molecules--C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol. 2005; 25(6):582-91. DOI: 10.1007/s10875-005-7828-2. View

12.

Chen H, Tsai W, Leu H, Ho H, Liou L . Invasive fungal infection in systemic lupus erythematosus: an analysis of 15 cases and a literature review. Rheumatology (Oxford). 2006; 46(3):539-44. DOI: 10.1093/rheumatology/kel343. View

13.

van Tuyl L, Felson D, Wells G, Smolen J, Zhang B, Boers M . Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken). 2010; 62(1):108-17. PMC: 2905735. DOI: 10.1002/acr.20021. View

14.

Aletaha D, Funovits J, Breedveld F, Sharp J, Segurado O, Smolen J . Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum. 2009; 60(5):1242-9. DOI: 10.1002/art.24433. View

15.

Wolfe F . The many myths of erythrocyte sedimentation rate and C-reactive protein. J Rheumatol. 2009; 36(8):1568-9. DOI: 10.3899/jrheum.090386. View

16.

Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B . Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001; 29(7):1404-7. DOI: 10.1097/00003246-200107000-00017. View

17.

Rollins B . Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today. 1996; 2(5):198-204. DOI: 10.1016/1357-4310(96)88772-7. View

18.

Gong J, Ratkay L, Waterfield J, Clark-Lewis I . An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med. 1997; 186(1):131-7. PMC: 2198969. DOI: 10.1084/jem.186.1.131. View

19.

Fransen J, Moens H, Speyer I, Van Riel P . Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis. 2005; 64(9):1294-8. PMC: 1755664. DOI: 10.1136/ard.2004.030924. View

20.

Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N . Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis.... Ann Rheum Dis. 2007; 66(9):1221-6. PMC: 1955164. DOI: 10.1136/ard.2006.063834. View